Cabozantinib real‐world effectiveness in the first‐through fourth‐line settings for the treatment of metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium

BACKGROUND: Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. METHODS: Patients with mRCC treated with cabozantinib between 2011 and 2019 were i...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Cancer Med
Главные авторы: Gan, Chun Loo, Dudani, Shaan, Wells, J. Connor, Donskov, Frede, Pal, Sumanta K., Dizman, Nazli, Rathi, Nityam, Beuselinck, Benoit, Yan, Flora, Lalani, Aly‐Khan A., Hansen, Aaron, Szabados, Bernadett, de Velasco, Guillermo, Tran, Ben, Lee, Jae Lyun, Vaishampayan, Ulka N., Bjarnason, Georg A., Subasri, Mathushan, Choueiri, Toni K., Heng, Daniel Y. C.
Формат: Artigo
Язык:Inglês
Опубликовано: John Wiley and Sons Inc. 2021
Предметы:
Clinical Cancer Research
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC7926018/
https://ncbi.nlm.nih.gov/pubmed/33463028
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cam4.3717
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы